WO2008125902A3 - Peripheral and neural inflammatory crosstalk - Google Patents

Peripheral and neural inflammatory crosstalk Download PDF

Info

Publication number
WO2008125902A3
WO2008125902A3 PCT/IB2007/004351 IB2007004351W WO2008125902A3 WO 2008125902 A3 WO2008125902 A3 WO 2008125902A3 IB 2007004351 W IB2007004351 W IB 2007004351W WO 2008125902 A3 WO2008125902 A3 WO 2008125902A3
Authority
WO
WIPO (PCT)
Prior art keywords
crosstalk
peripheral
neural inflammatory
inflammatory
neural
Prior art date
Application number
PCT/IB2007/004351
Other languages
French (fr)
Other versions
WO2008125902A8 (en
WO2008125902A2 (en
Inventor
Stephanos Kyrkanides
M. Kerry O'banion
Ross H. Tallents
Original Assignee
University Of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Rochester filed Critical University Of Rochester
Priority to JP2009508550A priority Critical patent/JP2009538279A/en
Priority to AU2007349198A priority patent/AU2007349198A1/en
Priority to EP07873329A priority patent/EP2026777A2/en
Priority to US12/282,251 priority patent/US20100286233A1/en
Priority to CA002638622A priority patent/CA2638622A1/en
Publication of WO2008125902A2 publication Critical patent/WO2008125902A2/en
Publication of WO2008125902A8 publication Critical patent/WO2008125902A8/en
Publication of WO2008125902A3 publication Critical patent/WO2008125902A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99001—Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/99—Other intramolecular oxidoreductases (5.3.99)
    • C12Y503/99003—Prostaglandin-E synthase (5.3.99.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)

Abstract

Disclosed are compositions and methods for the study and treatment of inflammatory disease, neurological disorders, bone disease, pain, and methods of making and using thereof.
PCT/IB2007/004351 2006-03-09 2007-03-09 Peripheral and neural inflammatory crosstalk WO2008125902A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2009508550A JP2009538279A (en) 2006-03-09 2007-03-09 Peripheral and neural inflammatory crosstalk
AU2007349198A AU2007349198A1 (en) 2006-03-09 2007-03-09 Peripheral and neural inflammatory crosstalk
EP07873329A EP2026777A2 (en) 2006-03-09 2007-03-09 Peripheral and neural inflammatory crosstalk
US12/282,251 US20100286233A1 (en) 2006-03-09 2007-03-09 Peripheral and neural inflammatory crosstalk
CA002638622A CA2638622A1 (en) 2006-03-09 2007-03-09 Peripheral and neural inflammatory crosstalk

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78073406P 2006-03-09 2006-03-09
US60/780,734 2006-03-09
US80748106P 2006-07-15 2006-07-15
US60/807,481 2006-07-15

Publications (3)

Publication Number Publication Date
WO2008125902A2 WO2008125902A2 (en) 2008-10-23
WO2008125902A8 WO2008125902A8 (en) 2009-08-27
WO2008125902A3 true WO2008125902A3 (en) 2016-06-09

Family

ID=39864415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004351 WO2008125902A2 (en) 2006-03-09 2007-03-09 Peripheral and neural inflammatory crosstalk

Country Status (6)

Country Link
US (1) US20100286233A1 (en)
EP (1) EP2026777A2 (en)
JP (1) JP2009538279A (en)
AU (1) AU2007349198A1 (en)
CA (1) CA2638622A1 (en)
WO (1) WO2008125902A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105131067B (en) * 2010-03-24 2019-02-19 雷克西制药公司 RNA in skin and fibrotic conditions is interfered
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017096123A1 (en) * 2015-12-04 2017-06-08 The Penn State Research Foundation Chemical reprogramming of human glial cells into neurons with small molecule cocktail
EP3710016A4 (en) * 2017-11-17 2021-12-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for alleviating cytokine release syndrome
CN115541776B (en) * 2022-11-03 2024-01-19 北京大学第三医院（北京大学第三临床医学院） Method for detecting steroid hormone by utilizing high performance liquid chromatography-ion mobility differential mass spectrum

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807733A (en) * 1995-06-07 1998-09-15 Donald A Young Mammalian prostaglandin H synthase-2 fusion proteins
WO2001082946A2 (en) * 2000-04-28 2001-11-08 Curis, Inc. Neuroprotective compositions
US20030181426A1 (en) * 2002-02-11 2003-09-25 Eisenach James C. Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
WO2004073646A2 (en) * 2003-02-19 2004-09-02 University Of Rochester Treatment of pain through expression of opioid receptors
US20040192630A1 (en) * 2002-05-02 2004-09-30 Stephanos Kyrkanides Vectors having both isoforms of beta-hexosaminidase and uses of the same
US20060002937A1 (en) * 2004-06-10 2006-01-05 University Of Leicester Methods for treating conditions associated with MASP-2 dependent complement activation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807733A (en) * 1995-06-07 1998-09-15 Donald A Young Mammalian prostaglandin H synthase-2 fusion proteins
WO2001082946A2 (en) * 2000-04-28 2001-11-08 Curis, Inc. Neuroprotective compositions
US20030181426A1 (en) * 2002-02-11 2003-09-25 Eisenach James C. Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
US20040192630A1 (en) * 2002-05-02 2004-09-30 Stephanos Kyrkanides Vectors having both isoforms of beta-hexosaminidase and uses of the same
WO2004073646A2 (en) * 2003-02-19 2004-09-02 University Of Rochester Treatment of pain through expression of opioid receptors
US20060002937A1 (en) * 2004-06-10 2006-01-05 University Of Leicester Methods for treating conditions associated with MASP-2 dependent complement activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENKERT ET AL.: "Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti- inflammatory drug NS-398,but not by COX-2-specific RNA interference", ONCOGENE, vol. 22, no. 54, 2003, pages 8653 - 8661, XP002354595, DOI: doi:10.1038/sj.onc.1206920 *

Also Published As

Publication number Publication date
WO2008125902A8 (en) 2009-08-27
CA2638622A1 (en) 2007-09-09
WO2008125902A2 (en) 2008-10-23
US20100286233A1 (en) 2010-11-11
EP2026777A2 (en) 2009-02-25
AU2007349198A1 (en) 2008-10-23
JP2009538279A (en) 2009-11-05

Similar Documents

Publication Publication Date Title
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2006025991A3 (en) Isoindoline compounds and methods of making and using the same
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
EP1893216A4 (en) Methods and compositions for the treatment of ocular disorders
WO2004080423A3 (en) 7-amino- isoindolyl compounds amd their pharmaceutical uses
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
WO2008057252A3 (en) Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2007018797A8 (en) Selective nerve stimulation for the treatment of eating disorders
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
WO2006058867A3 (en) Substituted pteridines for the treatment of inflammatory diseases
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
EP1680145A4 (en) Methods and compositions for the treatment of neurological disease
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2006135694A3 (en) Uii-modulating compounds and their use
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2009508550

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2638622

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007349198

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007873329

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007349198

Country of ref document: AU

Date of ref document: 20070309

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12282251

Country of ref document: US